Cardiotoxicity of Anthracyclines

• DOI: 10.3389/fcvm.2020.00026
• Publication Date: 2020-03-18T04:28:41Z
• Authors: Daniela Cardinale; Fabiani Iacopo; Carlo Maria Cipolla
• Keywords: Cardiotoxicity; Subclinical infection

Cardiotoxicity is a relevant complication that may compromise the clinical use of anthracyclines, affecting quality life and overall survival in cancer patients, independently oncological prognosis. The paper provides an overview anthracycline-induced cardiotoxicity terms definition, classification, incidence, risk factors, possible mechanisms, diagnosis, treatment. We also reported effective strategies for preventing cardiotoxicity. Furthermore, we discussed limitation current approaches, need new early detection treatment Probably, unique continuous phenomenon starting with myocardial cell injury, followed by progressive left ventricular ejection fraction (LVEF) decline that, if disregarded not cured progressively leads to overt heart failure. Anthracycline-induced can be detected at preclinical phase, very much before onset failure symptoms or LVEF drops. role troponins identifying subclinical angiotensin-converting enzyme inhibitors prevent reduction strategy has emerged last fifteen years. If cardiac dysfunction already occurred, partial complete recovery still obtained promptly initiated.